Latest stories on CRSP
Forget Casgevy: CRISPR Therapeutics' Heart-Disease Data Could Matter More
The Motley Fool63 · neutralproduct/pr
The Outlook of CRISPR Therapeutics Stock Does Not Look Strong After Its CFO Resigns
Barchart34 · bearishgeneral
CRISPR Therapeutics Names A.J. Silver CFO as Raju Prasad Steps Down, Effective Today
October 20, 2026
MarketChameleon52 · neutralgeneral
Stocks to watch after hours: AGNC, WAL, and CRSP
Seeking Alpha53 · neutralgeneral
CRISPR Therapeutics CFO steps down
Seeking Alpha44 · neutralgeneral
Crispr Therapeutics CFO Raju Prasad to step down, A.J. Silver to succeed
The Fly44 · neutralgeneral
CRISPR Therapeutics AG (CRSP) files 8-K
SEC 8-K50 · neutralgeneral
CRISPR Therapeutics Announces Chief Financial Officer Transition
GlobeNewswire44 · neutralgeneral
CRISPR Therapeutics Announces Chief Financial Officer Transition
Business Insider44 · neutralgeneral
Where Will CRISPR Therapeutics Stock Be in 2030?
The Motley Fool57 · neutralgeneral
Cathie Wood Bought More CRISPR Therapeutics Stock 2 Days in a Row. Here's What She Sees in the Biotech Stock.
The Motley Fool64 · neutralgeneral
Crispr Therapeutics management to meet with Piper Sandler
The Fly56 · neutralgeneral
Crispr Therapeutics initiated with a Neutral at UBS
The Fly48 · neutralanalyst
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Stocktwits News48 · neutralgeneral
CRISPR Therapeutics Puts CTX310 Phase 1b Severe Hypertriglyceridemia Data on the AHA 2026 Late-Breaking Stage
October 9, 2026
MarketChameleon58 · neutralproduct/pr
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
The Motley Fool64 · neutralanalyst
Crispr Therapeutics price target lowered to $81 from $82 at BofA
The Fly44 · neutralanalyst
H.C. Wainwright reiterates Buy on CRISPR stock, $80 target
Investing.com Analyst Ratings61 · neutralanalyst
CRISPR Therapeutics targets an AHA 2026 spotlight with late-breaking Phase 1b CTX310 data in severe hypertriglyceridemia
October 8, 2026
MarketChameleon58 · neutralproduct/pr
CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026
StockTitan58 · neutralproduct/pr